- 1 Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related
- 2 hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a
- 3 nationwide Danish cohort study
- 4 Mie Agermose Gram<sup>1\*</sup>, Hanne-Dorthe Emborg<sup>1</sup>, Astrid Blicher Schelde<sup>1</sup>, Nikolaj Ulrik Friis<sup>1</sup>, Katrine Finderup
- 5 Nielsen<sup>1</sup>, Ida Rask Moustsen-Helms<sup>1</sup>, Rebecca Legarth<sup>2</sup>, Janni Uyen Hoa Lam<sup>2</sup>, Manon Chaine<sup>2</sup>, Aisha Zahoor
- 6 Malik<sup>2</sup>, Morten Rasmussen<sup>3</sup>, Jannik Fonager<sup>3</sup>, Raphael Niklaus Sieber<sup>4</sup>, Marc Stegger<sup>4</sup>, Steen Ethelberg<sup>1,5</sup>,
- 7 Palle Valentiner-Branth<sup>1</sup>, Christian Holm Hansen<sup>1</sup>
- 8 Affiliations
- 9 <sup>1</sup> Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen,
- 10 Denmark.
- 11 <sup>2</sup> Division of Infectious Disease Preparedness, Data Integration and Analysis, Statens Serum Institut,
- 12 Copenhagen, Denmark.
- 13 <sup>3</sup> Department of Virus Research and Development Laboratory, Virus and Microbiological Special Diagnostics,
- 14 Statens Serum Institut, Copenhagen, Denmark.
- <sup>4</sup> Department of Bacteria, Parasites, and Fungi, Statens Serum Institut, Copenhagen, Denmark.
- <sup>5</sup> Department of Public Health, Global Health Section, University of Copenhagen, Copenhagen, Denmark.
- 18 Corresponding author
- 19 MIAG@ssi.dk (MIAG)

20

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### **Abstract**

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Background

The continued occurrence of more contagious SARS-CoV-2 variants and waning immunity over time require

ongoing re-evaluation of the vaccine effectiveness (VE). This study aimed to estimate the effectiveness in two

age groups (12-59 and 60 years or above) of two and three vaccine doses (BNT162b2 mRNA or mRNA-1273

vaccine) by time since vaccination against SARS-CoV-2 infection and COVID-19-related hospitalization in an

Alpha, Delta and Omicron dominated period.

### Methods

A Danish nationwide cohort study design was used to estimate VE against SARS-CoV-2 infection and COVID-

19-related hospitalization with the Alpha, Delta and Omicron variants. Information was obtained from

nationwide registries and linked using a unique personal identification number. The study included all

residents in Denmark aged 12 years or above (18 years or above for the analysis of three doses) in the Alpha

(February 20 to June 15, 2021), Delta (July 4 to November 20, 2021) and Omicron (December 21, 2021 to

January 31, 2022) dominated periods. VE estimates including 95% confidence intervals (CIs) were calculated

using Cox proportional hazard regression models with adjustments for age, sex and geographical region.

Vaccination status was included as a time-varying exposure.

#### **Findings**

In the oldest age group, VE against infection after two doses was 91.0% (95% CI: 88.5; 92.9) for the Alpha

variant, 82.2% (95% CI: 75.3; 87.1) for the Delta variant and 39.9% (95% CI: 26.4; 50.9) for the Omicron variant

14-30 days since vaccination. The VE waned over time and was 71.5% (95% CI: 54.7; 82.8), 49.8% (95% CI:

46.5; 52.8) and 4.7% (95% CI: 0.2; 8.9) >120 days since vaccination against the three variants, respectively.

Higher estimates were observed after the third dose with VE estimates against infection of 86.0% (Delta, 95%

CI: 83.3; 88.3) and 57.6% (Omicron, 95% CI: 55.8; 59.4) 14-30 days since vaccination. Among both age groups,

VE against COVID-19-related hospitalization 14-30 days since vaccination with two or three doses was 94.8%

or above for the Alpha and Delta variants, whereas among the youngest age group, VE estimates against the

Omicron variant after two and three doses were 62.4% (95% CI: 46.3; 73.6) and 89.8% (95% CI: 87.9; 91.3),

respectively.

#### **Conclusions**

Two vaccine doses provided high protection against SARS-CoV-2 infection and COVID-19-related

hospitalization with the Alpha and Delta variants with protection waning over time. Two vaccine doses

provided only limited protection against SARS-CoV-2 infection and COVID-19-related hospitalization with the

Omicron variant. The third vaccine dose substantially increased the protection against Delta and Omicron.

## Background

Mass vaccination of the population is a key strategy to manage the coronavirus disease 2019 (COVID-19) pandemic. However, breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in vaccinated individuals still present a public health challenge (1-3). Multiple studies have assessed COVID-19 vaccine effectiveness (VE) against SARS-CoV-2 infection and severe COVID-19-related outcomes (4-10). A systematic review and meta-regression demonstrated that the VE against SARS-CoV-2 infection and symptomatic disease decreased more than against severe disease six months after two doses (9). However, all the included studies were carried out before the circulation of the Omicron variant (9). The SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.617.2 (Delta) and B.1.1.529 (Omicron) caused rapid increase of SARS-CoV-2 infections worldwide (11) and were classified as variants of concern (VOC) by the World Health Organization (12). Continued emergence of new variants and waning immunity by time since vaccination (3) requires ongoing evaluation of the VE to inform future vaccination strategies. A Danish preprint study has estimated the protection of COVID-19 mRNA vaccines against infection or hospitalization with the Omicron variant and

observed relatively poor protection against infection but high VE against COVID-19-related hospitalization after the third dose (13). However, previous studies have observed differences in the VE against SARS-CoV-2 infection with the Alpha, Delta and Omicron variants (4-10) and only few large-scale studies have compared VE against all three variants (10). Despite variation between the variants, a previous study of the risk of hospitalization and death associated with the Delta and Omicron variants observed a significant variation with age (14). The aim of this study was to estimate the effectiveness of two and three doses of the BNT162b2 mRNA (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccine against SARS-CoV-2 infection and COVID-19-related hospitalization in an Alpha, Delta and Omicron dominant period by time since vaccination in two age groups (12-59 years and 60 years or above).

# Methods

- 78 Study design and setting
- 79 We conducted a nationwide cohort study in Denmark. All residents in Denmark are registered in the Danish
- 80 Civil Registration System (CRS) with a unique personal identification number (CPR number), which is used in
- 81 all national registries, enabling individual-level linkage between registries (15).

#### The Danish COVID-19 vaccination program

The rollout of COVID-19 vaccines in Denmark was initiated on December 27, 2020. The BNT162b2 mRNA vaccine from Pfizer/BioNTech and the mRNA-1273 vaccine from Moderna are part of the Danish vaccination program. In Denmark, all residents aged 5 years or above are offered two vaccine doses, and those aged 18 years or above are offered a third vaccine dose 4.5 months after the second dose. Denmark has continuously received vaccines during the COVID-19 vaccination rollout. However, relatively few vaccines were available in the initial phase. Hence, the Danish Health Authority determined the order in which population groups

were offered vaccination. The populations initially prioritized for COVID-19 vaccination were the most vulnerable citizens and frontline healthcare workers whereas the younger population was invited later (16).

#### **SARS-CoV-2 testing**

One of Denmark's main strategies for handling the COVID-19 epidemic was mass testing including unlimited access to free-of-charge SARS-CoV-2 RT-PCR tests at either community testing facilities or hospitals, and rapid antigen tests at a community level. As part of the re-opening of Denmark, a recent negative RT-PCR or rapid antigen test was required for unvaccinated individuals to access indoor public facilities (from March 1 to October 1, 2021, and again from November 11, 2021 to February 1, 2022). These initiatives have ensured a high testing rate for SARS-CoV-2, and the rate of RT-PCR testing in the Danish population is among the highest in the world (11). During the entire study period, it was recommended that a positive rapid antigen test was verified by RT-PCR.

### Study population

The study population included all residents in Denmark aged 12 years or above (18 years or above for three doses) in an Alpha, Delta and an Omicron dominant period. Individuals aged 5-11 years were offered vaccination later and vaccinated with a smaller dose than individuals aged 12 years or above (19). Therefore, we did not included individuals younger than 12 years in the study. Individuals vaccinated with other COVID-19 vaccines than BNT162b2 mRNA or mRNA-1273 were censored at the time of vaccination. Individuals with a reverse transcription polymerase chain reaction (RT-PCR)-confirmed SARS-CoV-2 infection before the start of the study periods and those without any tests during the three variant periods were excluded from the analyses. Only the first positive PCR-test was included.

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

Assessment of exposure All administered COVID-19 vaccines are registered in the Danish Vaccination Registry (DVR) on an individual level, identified by the CPR number (17). Information on the date of vaccine administration and name of the vaccine product was retrieved from the DVR (17). Assessment of outcomes (SARS-CoV-2 infection and COVID-19-related hospitalization) The Danish Microbiology Database (MiBa) receives, in real-time, copies of all laboratory test results from all clinical microbiology departments in Denmark (18). During the COVID-19 pandemic, community-testing facilities were established across the nation, and in early 2021, it became mandatory for private vendors performing SARS-CoV-2 testing to report electronically to MiBa (18). Data on all positive laboratoryconfirmed RT-PCR tests were extracted from MiBa (18). Information on rapid antigen tests was not included in this study due to moderate sensitivity in asymptomatic patients compared with RT-PCR (19). All hospitalizations are registered in an individually identifiable format in the Danish National Patient Registry with date of admission and discharge as well as diagnoses coded according to the International Classification of Diseases, 10th revision (ICD-10) (20). A COVID-19-related hospital admission was defined as any new admission lasting at least 12 hours and occurring between two days before and 14 days after the sample date where SARS-CoV-2 infection with either the Alpha, Delta or Omicron variant was detected. Covariates Information on age (5-years-intervals), sex (male/female) and geographical region (Capital Region of Denmark/Central Denmark Region/Northern Denmark Region/Region Zealand/Region of Southern Denmark) was included as covariates for the association between COVID-19 vaccination and SARS-CoV-2 infection or COVID-19-related hospitalization. Information on all covariates was extracted from the CRS registry (15).

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

Statistical analysis Characteristics of the study population were described using proportions and stratified by vaccination status. Time until SARS-CoV-2 infection (both asymptomatic and symptomatic) or COVID-19-related hospitalization were analyzed in three periods where the relevant variant accounted for at least 75% of all whole-genome sequenced (WGS) RT-PCR confirmed cases: Alpha (February 20 to June 15, 2021), Delta (July 4 to November 20, 2021) and Omicron (December 21, 2021 to January 31, 2022) (Fig 1). Separate models were fitted to estimate the VE for the two outcomes, SARS-CoV-2 infection and COVID-19related hospitalization, and separately for the analysis of two and three doses. Event rates in the vaccinated and unvaccinated exposure groups were compared using hazard ratios estimated in a Cox regression model adjusted for age group, sex and geographical region, with calendar time as the underlying time scale to control for temporal variations in the infection rate. VE was estimated as 1 minus the hazard ratio. Vaccinated individuals were followed from the start of the study or the date of assumed protection after the second or third vaccine dose, i.e. 14 days since vaccination. All individuals remained in follow-up until the date of SARS-CoV-2 infection, booster vaccination (third dose), death, emigration or the end of study period, whichever occurred first. Unvaccinated individuals remained in follow-up from the start of the study and until the date of their first vaccination, death, emigration, SARS-CoV-2 infection or end of the study, whichever occurred first. Exposure status was categorized as either unvaccinated or vaccinated with the last dose administered in the past 14-30 days, 31-60 days, 61-90 days, 91-120 days or >120 days. Time falling outside of these categories was not included in the analysis. Data were analyzed using SAS version 9.4.

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

Ethical considerations According to Danish law, ethical approval is not required for anonymized aggregated register-based studies. The study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (Table S1 STROBE checklist) (21). **Results** In the Delta dominant period, fewer individuals aged 60 years or above were unvaccinated compared to the Alpha dominant period. In the Omicron dominant period, the majority in both age groups was vaccinated with two or three doses. In the Alpha and Delta dominant period, the median age within each age group was slightly lower in the unvaccinated individuals compared to individuals vaccinated with two or three doses. Across all periods and age groups, the majority of the study population was vaccinated with the BNT162b2 mRNA vaccine (84.9-98.0%) (Table 1). Table 1. Characteristics of the study population by vaccination status. From a high proportion of all SARS-CoV-2 infections, with a median of 77% and 87% mid (<3,000 Ns) and high quality (>150 Ns) genomes were obtained using whole-genome sequencing (WGS) during the Alpha and Delta periods (Fig 1) as previously described (22). A lower median proportion was whole-genome sequenced during the Omicron period (6%) (Fig 1) due to the very high SARS-CoV-2 infection rate and a WGS capacity of 15,000 samples per week (23). However, samples were randomly selected for WGS by an algorithm from all positive samples with cycle threshold (Ct) values below 35.

Fig 1. Percentage of whole-genome sequenced samples and the distribution of SARS-CoV-2 variants by sample date.

The elderly were the first to be vaccinated with both the second and the third dose (Fig 2). Overall, the vaccination coverage was high in the study population. The vaccination coverage on January 31, 2022 for two doses was 85% among individuals aged 12-59 and 95% in those 60 years or older. The vaccination coverage on January 31, 2022 for three doses was 64% and 90% among individuals aged 18-59 and 60 years or above, respectively. Therefore, few individuals contributed with follow-up time as unvaccinated (reference group), especially in the Delta and Omicron dominant periods (Fig 2).

- Fig 2. Percentage vaccinated with two doses of BNT162b2 mRNA or mRNA-1273 by age groups.
- 190 Fig 3. Percentage vaccinated with three doses of BNT162b2 mRNA or mRNA-1273 by age groups.

### Vaccine effectiveness against SARS-CoV-2 infection after two doses

In the Alpha dominant period among individuals aged 60 or above, VE after two doses was 91.0% (95% CI: 88.5; 92.9) 14-30 days since vaccination. The estimates for the subsequent time periods decreased and were 71.5% (95% CI: 54.7; 82.1) >120 days since vaccination. In comparison, the two dose VE against SARS-CoV-2 infection with the Delta variant in individuals aged 60 years or above was 82.2% (95% CI: 75.3; 87.1) at 14-30 days since vaccination. Subsequently, the VE estimates decreased to 49.8% (95% CI: 46.5; 52.8) >120 days since vaccination. Slightly higher estimates were observed among individuals aged 12-59 years, where VE against SARS-CoV-2 infection with the Delta variant was 92.2% (95% CI: 91.8; 92.6) 14-30 days since vaccination and decreased to 64.9% (95% CI: 64.0; 65.8) >120 days since vaccination. Markedly lower two dose VE estimates were observed against SARS-CoV-2 infection with the Omicron variant for both age groups.

Among individuals aged 12-59 years, VE was 39.8% (95% CI: 38.4; 41.2) 14-30 days after vaccination. The estimates decreased to 13.2% (95% CI: 12.5; 13.9) >120 days since vaccination. Similar estimates but with wider CIs were observed among individuals aged 60 years or above (Table 2 and Fig 4).

Table 2. Adjusted vaccine effectiveness of two doses BNT162b2 mRNA or mRNA-1273 against SARS-CoV-2 infection with the Alpha, Delta and Omicron variants by age groups (12-59 years and 60 years or above).

Fig 4. Adjusted vaccine effectiveness against SARS-CoV-2 infection after two doses BNT162b2 mRNA or mRNA-1273 by SARS-CoV-2 variants and age groups.

#### Vaccine effectiveness against SARS-CoV-2 infection after three doses

Similar to the VE estimates after two doses, the VE after three doses was markedly lower against SARS-CoV-2 infection with the Omicron variant than that against the Alpha and Delta variants, although the VE against the Omicron variant was higher after three than after two doses and with less waning by time since vaccination (Table 2 and Table 3). Among individuals aged 18-59 years, VE against SARS-CoV-2 infection with the Delta variant was 89.5% (95% CI: 87.7; 91.0) 14-30 days since vaccination and 83.5% (95% CI: 69.4; 91.1) 61-90 days since vaccination. Similar estimates were observed among individuals aged 60 years or above. In comparison, for individuals aged 18-59 years, VE after three doses against SARS-CoV-2 infection with the Omicron variant was 55.2% (95% CI: 54.7; 55.6) 14-30 days since vaccination and 49.9% (95% CI: 46.5; 53.1) >120 days since vaccination. Among individuals aged 60 years or above, VE against SARS-CoV-2 infection with the Omicron variant after three doses was 57.6% (95% CI: 55.8; 59.4) 14-30 days since vaccination and 52.8% (95% CI: 49.3; 56.0) >120 days since vaccination (Table 3 and Fig 5).

Table 3. Adjusted vaccine effectiveness of three doses BNT162b2 mRNA or mRNA-1273 against SARS-CoV-2

infection with the Delta and Omicron variants by age groups (18-59 years and 60 years or above).

Fig 5. Adjusted vaccine effectiveness against SARS-CoV-2 infection after three doses BNT162b2

mRNA or mRNA-1273 by SARS-CoV-2 variants and age groups.

#### Vaccine effectiveness against COVID-19-related hospitalization after two doses

A high VE against COVID-19-related hospitalization after two doses was observed for both the Alpha and Delta variants. However, only limited protection was observed against COVID-19-related hospitalization following infection with the Omicron variant (Table 4). Among individuals aged 60 years or above, VE against COVID-19-related hospitalization with the Alpha and Delta variants after two doses was 96.4% (95% CI: 92.6; 98.3) and 100% (95% CI was not estimated as no hospital admissions were observed), respectively, 14-30 days since vaccination. The estimates decreased to 90.5% (Alpha, 95% CI: 67.0; 97.2) and 86.2% (Delta, 95% CI: 84.2; 87.9) >120 days since vaccination. For the Delta variant, similar estimates were observed among individuals aged 12-59 years (Table 4). Among individuals aged 12-59 years, VE against COVID-19-related hospitalization following infection with the Omicron variant was 62.4% (95% CI: 46.3; 73.6) 14-30 days since vaccination and 65.9% (95% CI: 62.0; 69.4) >120 days since vaccination. It was not possible to estimate two dose VE against COVID-19-related hospitalization following infection with the Omicron variant among individuals aged 60 years or above due to few cases, and since the majority of this group had already received a third vaccine dose at this time (Table 4 and Fig 6).

Table 4. Adjusted vaccine effectiveness of two doses BNT162b2 mRNA or mRNA-1273 against COVID-19-related hospitalization following infection with the Alpha, Delta and Omicron variants by age groups (12-59 years and 60 years or above)

Fig 6. Adjusted vaccine effectiveness against COVID-19-related hospitalization after two doses BNT162b2 mRNA or mRNA-1273 by SARS-CoV-2 variants and age groups.

### Vaccine effectiveness against COVID-19-related hospitalization after three doses

For both age groups, small absolute differences were observed in the VE estimates of three doses against COVID-19-related hospitalization between the Delta and Omicron variants. However, no waning was observed for the Delta variant while the estimates indicated waning over time against COVID-19-related hospitalization following infection with the Omicron variant. However, the available time interval after vaccination during the Delta period was shorter. In individuals aged 18-59 years, VE against COVID-19-related hospitalization following infection with the Delta variant was 94.8% (95% CI: 85.9; 98.1) 14-30 days and 68.4% (95% CI: 41.4; 83.0) 31-60 days since vaccination. In individuals aged 60 years or above, VE against COVID-19-related hospitalization following infection with the Delta variant was 96.6% (95% CI: 93.9; 98.1) 14-30 days and 91.4% (95% CI: 79.8; 96.4) 61-90 days since vaccination. In comparison, in individuals aged 18-59 years, VE against COVID-19-related hospitalization following infection with the Omicron variant was 89.8% (95% CI: 87.9; 91.3) 14-30 days since vaccination. From then on, a gradual decline in VE was observed reaching 33.3% (95% CI: 0.9; 55.1) >120 days since vaccination. A smaller decrease in the VE against COVID-19-related hospitalization following infection with the Omicron was observed among individuals aged 60 years or above with an estimated VE of 94.4% (95% CI: 93.0; 95.5) 14-30 days and 77.3% (95% CI: 70.9; 82.3) >120 days since vaccination (Table 5 and Fig 7).

Table 5. Adjusted vaccine effectiveness of three doses BNT162b2 mRNA or mRNA-1273 against COVID-19-related hospitalization following infection with the Delta and Omicron variants by age groups (18-59 years

Fig 7. Adjusted vaccine effectiveness against COVID-19-related hospitalization after three doses BNT162b2 mRNA or mRNA-1273 by SARS-CoV-2 variants and age groups.

### Discussion

and ≥60 years)

Compared to unvaccinated individuals, vaccination with two or three doses of BNT162b2 mRNA or mRNA1273 was associated with protection against infection with the Alpha, Delta and Omicron SARS-CoV-2
variants, peaking 14-30 days since vaccination with either two or three doses. However, the protection
against infection with the Omicron variant was markedly lower compared to infection with the Alpha or Delta
variants. The protection against infection with the three variants afforded by vaccination after two doses
decreased with time since vaccination. However, the VE against infection with the Delta and Omicron variants
decreased less over time after three doses. High protection and less pronounced waning were observed
against COVID-19-related hospitalization following infection with the Alpha and Delta variants after two
doses. However, the third dose contributed to greater levels of protection against COVID-19-related
hospitalization following infection especially with the Omicron variant. It was unexpected that individuals
aged 12-59 years had slightly lower VE against infection with the Omicron variant in all time intervals
compared to individuals aged 60 years or above. This may be explained by biases introduced in nonrandomized studies including differences in behavior between unvaccinated and vaccinated individuals (24).

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

Our results for the VE against SARS-CoV-2 infection with the Alpha and Delta variants align with those of a test-negative case-control study from England that observed a slightly higher VE against SARS-CoV-2 infection with the Alpha variant compared to the Delta variant after two doses of the BNT162b2 mRNA vaccine (4). They observed a VE against SARS-CoV-2 infection with the Alpha and Delta variants of 93.7% (95% CI: 91.6; 95.3) and 88.0% (95% CI: 85.3; 90.1), respectively (4). However, in a study from the UK, similar VE estimates against infection with the Alpha (78% (95% CI: 68; 84)) or Delta (80% (95% CI: 77; 83)) variants after two doses of BNT162b2 mRNA were observed (5). Previous studies have observed markedly higher protection against infection with the Delta variant compared to the Omicron variant (6-8). A test-negative case-control study from Southern California found that VE against infection with the Delta variant after two doses of mRNA-1273 was high and waned slowly with VE of 80.2% (95% CI: 68.2; 87.7) and 61.3% (95% CI: 55.0; 66.7) 14-90 days and >270 days since vaccination, respectively (8). Furthermore, they observed VE against hospitalization with the Delta variant of ≥99% after two and three doses (8). Similar to our study, a testnegative case-control study from England also observed waning over time and that a third dose contributed to greater levels of protection (7). They observed that VE against infection with the Delta variant after two doses BNT162b2 mRNA was 90.9% (95% CI: 89.6; 92.0) 2-4 weeks since vaccination and declined to 62.7% (95% CI: 61.6; 63.7) ≥25 weeks since vaccination. After the third dose, the VE against infection with the Delta variant was 95.1% (95% CI: 94.8; 95.4) 2-4 weeks since vaccination and declined to 89.9% (95% CI: 89.2; 90.5) ≥10 weeks since vaccination (7). The VE was higher with the mRNA-1273 vaccine (7). For the Omicron variant, the study from Southern California observed only a modest protection of 44.0% (95% CI: 35.1; 51.6) against infection 14-90 days since vaccination with two doses mRNA-1273 (8). The VE decreased quickly thereafter to 23.5% (95% CI: 16.4; 30.0) 91-180 days and 5.9% (95% CI: 0.04-11.0) >270 days since vaccination (8). Similar to our results, the VE against infection with the Omicron variant increased after the third dose (8). However, they observed higher VE estimates against hospitalization with the Omicron variant compared to our study with estimates of 84.5% (95% CI: 23.0; 96.9) and 99.2% (95% CI: 76.3; 100.0) after two and three doses, respectively (8).

A test-negative case-control study from England observed limited protection against symptomatic disease caused by the Omicron variant but reported that a third dose substantially increased protection (7). Their observed VE estimates were higher and waned faster after the third dose than observed in our study. VE against infection with the Omicron variant was 65.5% (95% CI: 63.9; 67.0) and 8.8% (95% CI: 7.0; 10.5) 2-4 weeks and ≥25 weeks since vaccination, respectively (7). After the third dose, VE against infection with the Omicron variant was 67.2% (95% CI: 66.5; 67.8) and 45.7% (95% CI: 44.7; 46.7) 2-4 weeks and ≥10 weeks since vaccination, respectively (7). An explanation to the lower estimates in our study may be that we estimated VE against SARS-CoV-2 infection regardless of the symptom status.

Strengths and limitations

The strengths of this study are the large scale of testing for SARS-CoV-2 including unlimited and easily accessible free-of-charge RT-PCR tests, as well as the ability to individually link data on all residents in Denmark across the nationwide high-quality registries. The high sensitivity (97.1%) and specificity (99.98%) observed for the RT-PCR test (21) minimize the risk of misclassification of the outcome. However, we were not able to discriminate between asymptomatic and symptomatic infections. In addition, a previous study has observed an inherent increased transmissibility of the Omicron sub-linage BA.2 (22) and we cannot rule out that the VE differs between the Omicron sub-linages. BA.1 and BA.2 was the most frequent Omicron sub-linages in Denmark (25). BA.1 was most prevalent in the beginning of the included Omicron dominated period. However, the prevalence of BA.2 has been increasing faster than BA.1 (25). Due to the short BA.1 dominated period, it was not possible to separate the VE analysis by BA.1 and BA.2.

COVID-19-related hospitalization was defined as an all-cause hospital admission lasting at least 12 hours and occurring up to 14 days after or two days before a positive SARS-CoV-2 test. Some of the hospitalizations included in our analysis will therefore have been caused by other factors than COVID-19. Assuming that the rate of hospitalization due to other causes is similar in the vaccinated and unvaccinated populations, the lack

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

of specificity in the definition may have resulted in an underestimation of the VE. In addition, an effort was made to ensure equal access to COVID-19 vaccination for all Danish residents. This was done through an online booking system, special campaigns, offering vaccination in some workplaces, translating the information about COVID-19 vaccination to several languages and arranging transport and pop-up vaccination for those who were not able to reach the vaccination clinics on their own. However, the populations initially prioritized for COVID-19 vaccination were the most vulnerable citizens and frontline healthcare workers whereas the younger population was invited later. Therefore, it was not possible to estimate VE of two and three doses for both age groups in all defined periods. No individuals had received the third dose in the Alpha dominant period and the majority of the oldest age group had already received third vaccine dose in the Omicron dominant period. In general, non-randomized studies assessing COVID-19 VE can easily be flawed (24), which may also apply to this study. Although we adjusted the Cox regression models for potential confounders (calendar time, age, sex and geographical region), we cannot exclude time-varying factors such as test frequency and differences in behavior or adherence to COVID-19 guidelines between vaccinated and unvaccinated, which may impact infection exposure. Vaccinated individuals may be more frequently tested (and thus more likely to document infection) if they are more health-conscious compared with unvaccinated individuals. The vaccinated individuals may be less frequently tested, if the vaccination reduces the severity of the infection and thus fewer infected people have symptoms. Furthermore, public health authorities may encourage more frequent testing for the unvaccinated (24). Furthermore, vaccinated individuals may become more heavily exposed to the virus after vaccination, if they feel liberated to engage in activities with more frequent and high-risk exposure (24). This phenomenon of risk compensation decreases the benefit of vaccination (26). However, some data have suggested little change in protective behavior early after vaccination (27). Overall, this study contributed with evidence of high vaccine protection against SARS-CoV-2 infection and importantly against hospitalization with the Alpha and Delta variants after two doses of BNT162b2 mRNA or mRNA-1273. A third dose seems necessary to maintain protection against infection for longer time and in particular to ensure good protection against COVID-19-related hospitalization with the Omicron variant. In the context of the current Omicron wave, it is notable that a third dose contributed to greater levels of protection against both infection and especially COVID-19-related hospitalization following infection with the Omicron variant.

# **Funding**

366

367

368

369

370

371

372

373

374

375

376

377

378

379

Not applicable as neither Statens Serum Institut nor any authors received funding for this study.

## Acknowledgement

The authors are grateful to the Danish Health Data Authority for their help in defining the population. We would also like to thank the Department of Data Integration and Analysis at Statens Serum Institut for data management.

### References

- 1. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet (London, England). 2021;398(10316):2093-100.
- Keehner J, Horton LE, Binkin NJ, Laurent LC, Pride D, Longhurst CA, et al. Resurgence of SARS CoV-2 Infection in a Highly Vaccinated Health System Workforce. The New England journal of medicine.
- 385 2021;385(14):1330-2.
- 386 3. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning
  387 Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021;385(24):e85.

- 388 4. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness
- 389 of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585-94.
- 390 5. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta KD, et al. Effect of Delta
- variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med.
- 392 2021;27(12):2127-35.
- 393 6. Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association
- 394 Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2
- 395 Omicron and Delta Variants. JAMA. 2022;327(7):639-51.
- 396 7. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine
- 397 Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022.
- 398 8. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273
- against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022.
- 400 9. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of
- 401 effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review
- 402 and meta-regression. Lancet. 2022.
- 403 10. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity
- of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2
- 405 variants in the United States: prospective observational study. BMJ. 2022;376:e069761.
- 406 11. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus
- 407 (COVID-19) Cases. Our World in Data.
- 408 12. Tracking SARS-CoV-2 variants: World Health Organization; [cited 2022 24 April]. Available
- from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
- 410 13. Hansen C, Schelde A, Moustsen-Helm I, Emborg H-D, Eriksen R, Stegger M, et al. Vaccine
- 411 effectiveness against infection and COVID19-associated hospitalisation with the Omicron (B.1.1.529) variant

- 412 after vaccination with the BNT162b2 or mRNA-1273 vaccine: A nationwide Danish cohort study. Nature
- 413 Portfolio (Preprint). 2022.
- 414 14. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative
- analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta
- 416 (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303-12.
- 417 15. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in
- 418 epidemiology. Eur J Epidemiol. 2014;29(8):541-9.
- 419 16. Target groups for vaccination: The Danish Health Authority; [cited 2021 August 6]. Available
- 420 from: https://www.sst.dk/en/English/Corona-eng/Vaccination%20against%20COVID-
- 421 19/Who%20should%20be%20vaccinated.
- 422 17. Grove Krause T, Jakobsen S, Haarh M, Mølbak K. The Danish vaccination register. Euro
- 423 Surveill. 2012;17(17).
- 424 18. Schønning K, Dessau RB, Jensen TG, Thorsen NM, Wiuff C, Nielsen L, et al. Electronic
- 425 reporting of diagnostic laboratory test results from all healthcare sectors is a cornerstone of national
- preparedness and control of COVID-19 in Denmark. Apmis. 2021;129(7):438-51.
- 427 19. Fernandez-Montero A, Argemi J, Rodríguez JA, Ariño AH, Moreno-Galarraga L. Validation of a
- rapid antigen test as a screening tool for SARS-CoV-2 infection in asymptomatic populations. Sensitivity,
- 429 specificity and predictive values. EClinicalMedicine. 2021:100954.
- 430 20. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish
- 431 National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol.
- 432 2015;7:449-90.
- 433 21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
- 434 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for
- reporting observational studies. Int J Surg. 2014;12(12):1495-9.

- 436 22. Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CH, et al. Transmission
- 437 of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. medRxiv
- 438 (Preprint). 2022:2022.01.28.22270044.
- 439 23. Genomic overview of SARS-CoV-2 in Denmark: the Danish Covid-19 Genome Consortium;
- 440 [cited 2022 April 8]. Available from: https://covid19genomics.dk/statistics.
- 441 24. Ioannidis JPA. Factors influencing estimated effectiveness of COVID-19 vaccines in non-
- randomised studies. BMJ Evidence-Based Medicine. 2022:bmjebm-2021-111901.
- 443 25. Fonager J, Bennedbæk M, Bager P, Wohlfahrt J, Ellegaard KM, Ingham AC, et al. Molecular
- 444 epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2
- 445 January 2022. Euro Surveill. 2022;27(10).
- 446 26. Ioannidis JPA. Benefit of COVID-19 vaccination accounting for potential risk compensation.
- 447 NPJ Vaccines. 2021;6(1):99.
- 448 27. Goldszmidt R, Petherick A, Andrade EB, Hale T, Furst R, Phillips T, et al. Protective Behaviors
- 449 Against COVID-19 by Individual Vaccination Status in 12 Countries During the Pandemic. JAMA Netw Open.
- 450 2021;4(10):e2131137.

Table 1. Characteristics of the study population by vaccination status.

	Alph February 20 – J					elta mber 20, 2021			<b>Omicron</b> December 21, 2021 – January 31, 2022						
	60 years o			12-59 years	•	60 years or above				12-59 years	·	60 years or above			
	Unvaccinated	Two doses	Unvaccinated	Two doses	Three doses	Unvaccinated	Two doses	Three doses	Unvaccinated	Two doses	Three doses	Unvaccinated	Two doses	Three doses	
Number of individuals included	652,301	409,082	961,899	1,725,943	65,980	22,095	545,788	84,793	179,566	1,189,527	983,635	10,897	48,005	471,733	
Sex, n (%)															
Men	310,35	185,597	466,534	816,101	17,255	9,519	256,503	36,104	88,749	580,565	461,281	4,377	23,399	222,216	
	(47.6)	(45.4)	(48.5)	(47.3)	(26.2)	(43.1)	(47.0)	(42.6)	(49.4)	(48.8)	(46.9)	(40.2)	(48.7)	(47.1)	
Women	341,942	223,485	495,365	909,842	48,725	12,576	289,285	48,689	90,817	608,962	522,354	6,520	24,606	249,517	
	(52.4)	(54.6)	(51.5)	(52.7)	(73.8)	(56.9)	(53.0)	(57.4)	(50.6)	(51.2)	(53.1)	(59.8)	(51.3)	(52.9)	
Median age	68	73	29	37	47	67	69	75	29	29	44	66	64	69	
(IQR)	(64; 74)	(69; 77)	(21; 35)	(24; 48)	(38; 54)	(62; 74)	(64; 75)	(66; 84)	(21; 39)	(19; 39)	(32; 52)	(62; 74)	(61; 69)	(64; 76)	
Geographical region, n (%)															
Capital Region of	176,524	131,694	311,441	586,565	22,191	7,302	161,524	29,034	60,636	365,577	312,193	3,469	10,994	132,175	
Denmark	(27.1)	(32.2)	(32.4)	(34.0)	(33.6)	(33.0)	(29.6)	(34.2)	(33.8)	(30.7)	(31.7)	(31.8)	(22.9)	(28.0)	
Central Denmark	146,827	87,301	227,484	390,709	14,208	3,967	109,593	16,738	36,201	280,700	235,277	2,076	8,946	105,104	
Region	(22.5)	(21.3)	(23.6)	(22.6)	(21.5)	(18.0)	(20.1)	(19.7)	(20.2)	(23.6)	(23.9)	(19.1)	(18.6)	(22.3)	
Northern	75,954	41,881	88,096	164,329	6,366	2,036	61,024	8,163	16,130	124,310	94,906	1,011	7,030	49,839	
Denmark Region	(11.6)	(10.2)	(9.2)	(9.5)	(9.6)	(9.2)	(11.2)	(9.6)	(9.0)	(10.5)	(9.6)	(9.3)	(14.6)	(10.6)	
Region Zealand	98,855	56,828	118,070	228,836	8,886	3,728	90,175	13,131	28,034	157,087	132,258	1,911	9,457	73,576	
	(15.2)	(13.9)	(12.3)	(13.3)	(13.5)	(16.9)	(16.5)	(15.5)	(15.6)	(13.2)	(13.4)	(17.5)	(19.7)	(15.6)	
Region of Southern Denmark	154,141 (23.6)	91,378 (22.3)	216,808 (22.5)	355,504 (20.6)	14,329 (21.7)	5,062 (22.9)	123,472 (22.6)	17,727 (20.9)	38,565 (21.5)	261,853 (22.0)	209,001 (21.2)	2,430 (22.3)	11,578 (24.1)	111,039 (23.5)	
Vaccine product, n (%)															
BNT162b2 mRNA	0	378,474	0	1,464,639	64,691	0	499,477	80,527	0	970,777	858,689	0	42,829	433,412	
(Pfizer/BioNTech)	(0.0)	(92.5)	(0.0)	(84.9)	(98.0)	(0.0)	(91.5)	(95.0)	(0.0)	(81.6)	(87.3)	(0.0)	(89.2)	(91.9)	
mRNA-1273	0	30,608	0	261,304	1,289 (2.0)	0	46,311	4,266	0	218,750	124,946	0	5,176	38,321	
(Moderna)	(0.0)	(7.5)	(0.0)	(15.1)		(0.0)	(8.5)	(5.0)	(0.0)	(18.4)	(12.7)	(0.0)	(10.8)	(8.1)	

Individuals were able to contribute follow-up time in more than one time category.

<sup>\*18-59</sup> years for three doses.

Table 2. Adjusted vaccine effectiveness of two doses BNT162b2 mRNA or mRNA-1273 against SARS-CoV-2 infection with the Alpha, Delta and Omicron variants by age groups (12-59 years and 60 years or above)

			Alpha				Delta					Omicron					
	Population	Person- years	Cases	Adjusted VE	95% CI	Population	Person- years	Cases	Adjusted VE	95% CI	Population	Person- years	Cases	Adjusted VE	95% CI		
12-59 years																	
Unvaccinated						961,900	143,391	43,583	1 (reference)		179,566	15,483	96,239	1 (reference)			
Time since vaccination																	
14-30 days						1,600,368	74,050	1,623	92.2	91.8; 92.6	61,458	2,147	8,245	39.8	38.4; 41.2		
31-60 days						1,598,448	129,640	3,718	88.1	87.7; 88.5	63,908	3,018	16,503	31.6	30.5; 32.8		
61-90 days						1,581,102	123,576	7,873	80.8	80.3; 81.3	57,574	2,157	9,759	32.1	30.6; 33.5		
91-120 days						1,400,933	85,889	14,950	72.2	71.5; 72.8	221,118	7,015	22,907	31.4	30.3; 32.4		
>120 days						750,408	59,185	10,359	64.9	64.0; 65.8	1,075,946	56,886	276,028	13.2	12.5; 13.9		
60 years or above																	
Unvaccinated	652,301	111,187	4462	1 (reference)		22,095	6,894	1,113	1 (reference)		10,897	1,051	3,354	1 (reference)			
Time since vaccination																	
14-30 days	407,491	16,796	78	91	88.5; 92.9	199,219	6,996	59	82.2	75.3; 87.1	1,340	48	96	39.9	26.4; 50.9		
31-60 days	323,574	16,189	145	83.1	79.6; 86.0	360,046	21,964	393	74.3	69.9; 78.0	1,289	61	136	39.2	27.8; 48.8		
61-90 days	116,297	7,274	119	72.6	66.3; 77.8	447,280	34,207	687	77.4	74.4; 80.0	1,071	43	102	26.4	10.4; 39.6		
91-120 days	58,340	3,467	49	82.7	76.5; 87.2	496,174	38,464	1,161	69.8	66.7; 72.6	1,750	77	173	24.4	11.9; 35.1		
>120 days	35,698	1,445	24	71.5	54.7; 82.1	534,299	92,240	12,198	49.8	46.5; 52.8	45,844	1,783	4,722	4.7	0.2; 8.9		

VE = vaccine effectiveness. CI = confidence intervals. Person-years in days. VE estimates adjusted for five-year age groups, sex, and geographical region. Individuals were able to contribute follow-up time in more than one time category and (if vaccinated during the study period) to both the analysis of VE after two and three doses.

Table 3. Adjusted vaccine effectiveness of three doses BNT162b2 mRNA or mRNA-1273 against SARS-CoV-2 infection with the Delta and Omicron variants by age groups (18-59 years and 60 years or above)

			Delta			Omicron						
	Population	Person-years	Cases	Adjusted VE	95% CI	Population	Person-years	Cases	Adjusted VE	95% CI		
18-59 years												
Unvaccinated	757,824	110,495	34,414	1 (reference)		145,080	12,664	74,692	1 (reference)			
Time since vaccination		.,	- ,			-,		,	(			
14-30 days	65,955	2,200	155	89.5	87.7; 91.0	892,781	34,645	105,187	55.2	54.7; 55.6		
31-60 days	22,694	718	93	77.6	72.4; 81.7	641,642	20,388	89,239	50.8	50.2; 51.4		
61-90 days	4,087	74	10	83.5	69.4; 91.1	93,683	5,590	15,754	52.9	52.0; 53.7		
91-120 days						47,530	1,537	5,902	51.1	49.7; 52.5		
>120 days						6,415	227	979	49.9	46.5; 53.1		
60 years or above												
Unvaccinated	22,095	6,894	1,113	1 (reference)		10,897	1,051	3,354	1 (reference)			
Time since vaccination												
14-30 days	84,768	3,183	161	86	83.3; 88.3	335,455	12,712	13,485	57.6	55.8; 59.4		
31-60 days	48,428	2,612	188	82.9	79.5; 85.7	390,857	21,089	34,164	55.3	53.6; 56.9		
61-90 days	15,844	258	34	81.2	72.9; 87.0	177,842	7,035	10,409	58.3	56.5; 60.0		
91-120 days						78,411	3,947	5,361	56.6	54.4; 58.7		
>120 days						34,293	1,215	2,428	52.8	49.3; 56.0		

VE = vaccine effectiveness. CI = confidence intervals. VE estimates adjusted for five-year age groups, sex, and geographical region. Individuals were able to contribute follow-up time in more than one time category and (if vaccinated during the study period) to both the analysis of VE after two and three doses.

Table 4. Adjusted vaccine effectiveness of two doses BNT162b2 mRNA or mRNA-1273 against COVID-19-related hospitalization following infection with the Alpha, Delta and Omicron variants by age groups (12-59 years and 60 years or above)

			Alpha			Delta					Omicron					
	Population	Person- years	Cases	Adjusted VE	95% CI	Population	Person- years	Cases	Adjusted VE	95% CI	Population	Person- years	Cases	Adjusted VE	95% CI	
12-59 years		_														
Unvaccinated						961,900	143,391	934	1 (reference)		179,566	15,483	725	1 (reference)		
Time since vaccination																
14-30 days						1,600,368	74,050	6	99.1	98.0; 99.6	61,458	2,147	32	62.4	46.3; 73.6	
31-60 days						1,598,448	129,640	21	98.3	97.4; 98.9	63,908	3,018	67	51.4	37.4; 62.3	
61-90 days						1,581,102	123,576	18	98.4	97.4; 99.0	57,574	2,157	36	59.8	43.7; 71.3	
91-120 days						1,400,933	85,889	58	95.9	94.6; 96.9	221,118	7,015	84	61.4	51.3; 69.4	
>120 days						750,408	59,185	115	91.6	89.5; 93.2	1,075,946	56,886	673	65.9	62.0; 69.4	
60 years or above																
Unvaccinated	652,301	111,187	658	1 (reference)		22,095	6,894	287	1 (reference)							
Time since vaccination																
14-30 days	407,491	16,796	8	96.4	92.6; 98.3	199,219	6,996	0	100	*						
31-60 days	323,574	16,189	22	92.1	87.4; 95.1	360,046	21,964	8	97.7	95.2; 98.9						
61-90 days	116,297	7,274	25	82.5	72.1; 89.0	447,280	34,207	24	97.1	95.5; 98.1						
91-120 days	58,340	3,467	8	91	80.9; 95.7	496,174	38,464	44	96.3	94.7; 97.3						
>120 days	35,698	1,445	3	90.5	67.0; 97.2	534,299	92,240	855	86.2	84.2; 87.9						

VE = vaccine effectiveness. CI = confidence intervals. VE estimates adjusted for five-year age groups, sex, and geographical region. Individuals were able to contribute follow-up time in more than one time category and (if vaccinated during the study period) to both the analysis of VE after two and three doses.

<sup>\*</sup> It was not possible within the model to estimate a 95% confidence interval for the estimated vaccine effectiveness against COVID-19-related hospitalization with the Delta variant 14-30 days after the second dose as no COVID-19-related hospitalization were observed.

Table 5. Adjusted vaccine effectiveness of three doses BNT162b2 mRNA or mRNA-1273 against COVID-19-related hospitalization following infection with the Delta and Omicron variants by age groups (18-59 years and ≥60 years)

			Delta					Omicron		
	Population	Person-years	Cases	Adjusted VE	95% CI	Population	Person-years	Cases	Adjusted VE	95% CI
18-59 years										
Unvaccinated	757,824	110,495	911	1 (reference)		145,080	12,664	681	1 (reference)	
Time since vaccination										
14-30 days	65,955	2,200	4	94.8	85.9; 98.1	892,781	34,645	210	89.8	87.9; 91.3
31-60 days	22,694	718	11	68.4	41.4; 83.0	641,642	20,388	216	87.4	84.9; 89.6
61-90 days						93,683	5,590	97	80.5	75.4; 84.5
91-120 days						47,530	1,537	61	72.8	63.6; 79.7
>120 days						6,415	227	34	33.3	0.9; 55.1
60 years or above										
Unvaccinated	22,095	6,894	287	1 (reference)		10,897	1,051	298	1 (reference)	
Time since vaccination										
14-30 days						335,455	12,712	136	94.4	93.0; 95.5
31-60 days	84,768	3,183	13	96.6	93.9; 98.1	390,857	21,089	366	93.8	92.7; 94.7
61-90 days	48,428	2,612	44	89.1	84.3; 92.4	177,842	7,035	272	91.7	90.2; 93.0
91-120 days	15,844	258	6	91.4	79.8; 96.4	78,411	3,947	353	84.5	81.6; 87.0
>120 days	,				,	34,293	1,215	176	77.3	70.9; 82.3

VE = vaccine effectiveness. CI = confidence intervals. VE estimates adjusted for five-year age groups, sex, and geographical region. Individuals were able to contribute follow-up time in more than one time category and (if vaccinated during the study period) to both the analysis of VE after two and three doses.




Figure 1




Figure2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7